CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ: HLCS) announced today it has joined the Personalized Medicine Coalition (PMC), an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine. Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery and diagnostic markets. Helicos’ proprietary tSMSTM technology allows direct measurement of billions of strands of DNA enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine.
